Vivace Therapeutics disclosed preclinical efficacy for VT‑3989, a TEAD inhibitor that suppressed growth of NF2‑deficient meningioma models in vitro and in vivo. Company data show tumor growth inhibition in aggressive meningioma systems and support VT‑3989’s advancement into early clinical development for solid tumors, including refractory mesothelioma. The release frames VT‑3989 as a targeted approach against Hippo pathway–driven tumors where TEAD transcription factors are central to oncogenic transcription. TEAD inhibition here is presented as a precision strategy for tumors losing NF2 function; translational hurdles include central nervous system penetration and on‑target toxicity profiling.